Last articles

Ipilimumab for metastatic melanoma

Author : Pierre Allain Date : 2010-10-25

Ipilimumab is a human type monoclonal antibody which blocks the cytotoxic T- lymphocytes-associated antigen 4, CTLA-4, it is anti-CTLA-4.

According to a clinical trial published in the NEJM ipilimumab prolongs survival of patients with metastatic melanoma of 4 months, survival spending from 6 months to 10 months, but at the cost of significant adverse effects.

Your turn
User session
Bookmark, share this page
Bookmark and Share

© 2000-2019 CdM Editions / P. Allain. All rights reserved
Pharmacorama Charter